Jessica Bauman, MD, assistant professor in the Department of Hematology/Oncology at Fox Chase Cancer Center, Temple Health, shares details regarding different RET-fusion mutations in non-small cell lung cancer (NSCLC), placing emphasis primarily on KIF5B, which is seen in the majority of cases discussed in recent literature. Dr. Bauman observes that therapies targeting the different RET mutations with greater specificity are being studied increasingly which is important for improving treatment plans in patients with NSCLC.

Read the full interview transcript by clicking here.